So there’s a headline about a cancer blood test making the rounds this week that I cannot stop thinking about. Researchers at Princess Margaret Cancer Centre in Toronto are running a massive trial — 7,000 patients — testing whether a simple cancer blood test can detect microscopic traces of cancer DNA hiding in your bloodstream long before a CT scan would ever catch it. It’s called the SHERLOCK study, and lead investigator Dr. Lillian Siu says the early data is compelling: patients who test positive for this “molecular residual disease” have a very high chance of their cancer returning, and now they’re following thousands of people for years to prove it out.
One of the patients in the story, a 68-year-old guy named Paul who beat throat cancer, says the trial gave him something he hadn’t felt in years: reassurance. And I get that. I really do.
But my first reaction wasn’t relief. It was that old, familiar tightening in my chest — the one every single person in survivorship knows by name. Because here’s the thing nobody puts in the headline: a cancer blood test that can tell you your cancer is coming back is also a cancer blood test that can tell you your cancer is coming back. Full stop. Before you have any symptoms. Before there’s anything you can point to and say, “that’s why I feel off.” Just a number on a lab report, and the rest of your life to sit with it.
Welcome to the most complicated relationship I have with modern oncology and survivorship.
What This Cancer Blood Test Actually Is (The Non-Scary Explainer Version)
Quick and dirty, breastie-to-breastie: this cancer blood test is what’s called a liquid biopsy, and the tech behind it is circulating tumor DNA, or ctDNA. When tumor cells die off, they shed tiny fragments of their DNA into your bloodstream. If your treatment team already knows the genetic fingerprint of your original tumor, they can build a blood test that goes looking for that exact fingerprint, at concentrations so small that a scan or an MRI would never pick it up. Doctors call a positive result “molecular residual disease,” or MRD — meaning there’s still cancer somewhere in your body, it’s just too small to see yet.
This isn’t science fiction. It’s already being used clinically for some colorectal cancer patients, where up to 40% achieve what looks like a complete response to treatment before surgery, and doctors use ctDNA alongside scans and scopes to decide who can safely skip surgery altogether and who needs to stay in close surveillance. The FDA has granted Breakthrough Device Designation to at least one of these ctDNA tests for colorectal cancer, the agency’s way of fast-tracking review of technology that could meaningfully change how a serious disease is detected and treated.
And to be clear — this is genuinely exciting science. If a cancer blood test can flag recurrence months before imaging can, that’s a window where new immunotherapies or other treatments might actually intercept the disease before it takes hold again. For drug development, for clinical trial design, for building the next generation of treatments, this is enormous. I’m not here to throw shade at the science.
I’m here to talk about what it’s like to be the person the science is being done to.
The Other Shoe Has a Name Now, and It Comes With a Lab Requisition Form
If you’ve been in survivorship for any length of time, you already know the feeling I’m talking about. It’s the low hum underneath everything — the sense that you’re waiting for something. A phone call. A shadow on a scan. A ache that doesn’t go away fast enough. We live with what researchers politely call “fear of cancer recurrence,” and what I call the thing that moves into your head rent-free the day you’re told you’re “done” with treatment. Case in point, the last time I saw my oncologist for a checkup my blood pressure was 173/93 and the next day was 122/71…
It’s not a fringe experience, either. The American Cancer Society is blunt about it: worrying that your cancer will come back is a normal, common part of survivorship, and it’s usually most intense in that first year after treatment ends. ASCO’s own research puts fear of recurrence at the top of the list of unmet needs reported by cancer patients, tied to real, measurable drops in quality of life.
So now imagine giving that fear a cancer blood test.
On one hand — and I want to hold this genuinely, not sarcastically — some survivors would take certainty over uncertainty any single day of the week. Not knowing is its own kind of torture, and there’s an argument that a positive result at least gives you something to do: a new drug trial to enroll in, a doctor to call, a plan instead of a shrug. Dr. Siu herself says part of the hope behind SHERLOCK is easing “one of the biggest fears of cancer patients: that their cancer will come back.” I believe that’s a sincere goal.
On the other hand, what happens to the person who tests positive for a cancer blood test, and there is no next step yet? Right now, blood-based recurrence testing is explicitly not standard of care. Dr. Siu says it herself — these are still research tools, and doctors don’t yet have enough long-term data to know if catching MRD early actually changes outcomes, or just changes how long you get to sit with the news. That’s not a small caveat. That’s the whole ballgame.
Because here’s my fear, and it’s not a small one: we are getting very good at detection, and we are still catching up on what to do once we’ve detected something. A cancer blood test that tells you the cancer is coming back, with no proven intervention waiting on the other side of that news, isn’t treatment. It’s a countdown clock with no instructions.
A System Built to Treat, Not Prevent
This is the part that really sticks in my throat. Our healthcare system, for all its brilliance, is overwhelmingly reactive. We are extraordinary at treating disease once it announces itself. We are still catching up on the harder, less profitable, less flashy work of actually preventing it, or intercepting it early enough that “treatment” barely needs to happen.
A cancer blood test for recurrence sits right in that gap. It’s a detection tool dropped into a system that mostly still knows how to respond with the same three moves it’s always had: more scans, more chemo, more waiting. Until there’s a robust, evidence-backed intercept strategy for every MRD-positive result — not just for the lucky patients enrolled in a trial with an experimental arm — we’re handing people devastating information without necessarily handing them a next step. That’s not a criticism of the researchers, who are doing careful, honest work and say so themselves. It’s a criticism of a system that funds detection technology faster than it funds the follow-through.
I want this cancer blood test to exist. I want the SHERLOCK trial to succeed. I also want us to be honest, out loud, that knowing sooner is not automatically the same as living better — not until the system on the other end of that blood draw is ready to catch you.
So What Do You Do With All of This?
If you’re reading this as someone in survivorship, here’s my real, unfiltered advice:
- You get to have mixed feelings about this cancer blood test, and that’s not ingratitude. You can be grateful for the science and still not want it anywhere near your own body yet. Both things are allowed.
- “Not standard of care” is your permission slip to ask hard questions. If your oncologist brings this up, ask what they would actually do with a positive result today, not in five years.
- Fear of recurrence is not a personal failing. It’s one of the most well-documented psychological experiences in survivorship. You are not “being dramatic.” You’re being a person who survived something.
- You don’t have to optimize your anxiety away. Some of us cope by wanting every possible test. Some of us cope by wanting as few tests as possible. Neither is wrong.
I’ve written before about how survivorship messes with your nervous system in ways nobody warns you about, and I stand by every word of it. This blood test conversation is just the newest chapter in that same old story: the world keeps getting better at finding cancer, and we’re still building the emotional infrastructure to carry that knowledge without it swallowing us whole. If you want more on the science of why “scanxiety” lives in your body and not just your head, I wrote about that in Your Nervous System After Cancer: Why Survivorship Still Feels So Hard. And if what you need right now isn’t more data but a way to actually exhale, I still think about forest bathing more than almost anything else I’ve tried post-treatment.
I also broke down what else came out of this year’s big oncology meeting in ASCO 2026 and Breast Cancer: Survivorship, Fear of Recurrence, and the Growing Role of AI in Cancer Care — because this blood test conversation doesn’t exist in a vacuum. It’s part of a much bigger shift in how cancer care is starting to treat survivorship as a real, ongoing part of the journey instead of an afterthought once you “ring the bell.”
The Bottom Line
Science is racing ahead to detect cancer recurrence earlier than ever. I am not racing to catch up with my own capacity to sit with that information, and I don’t think you should feel pressure to either. This test could be genuinely life-saving for some patients down the line, especially as it gets paired with actual interventions. But until it is, let’s not pretend that “knowing sooner” is automatically a gift. Sometimes it’s just the other shoe, dropped a little earlier, onto a floor that isn’t ready to catch it yet.
Talk to your oncology team. Ask what a positive result of a cancer blood test would actually mean for your care plan today, not someday. And however you feel about all of this — relieved, terrified, both at once — that feeling is valid. You don’t need to apologize for any of it.
Sending you love, breasties. PS if you prefer video you can follow me over on YouTube
— Ellyn
Sources & further reading:
- American Cancer Society, Cancer Recurrence: Coping with the Fear It Will Come Back
- ASCO Educational Book, Fear of Cancer Recurrence or Progression: What Is It and What Can We Do About It?
- National Cancer Institute Colon and Rectal-Anal Task Forces, ctDNA Applications and Integration in Colorectal Cancer
- U.S. Food and Drug Administration, Breakthrough Devices Program
- MUSC Hollings Cancer Center, A Blood Test That Can Detect Cancer’s Return
- The Canadian Press (via Yahoo News), Can a Cancer Blood Test Tell Patients If Their Cancer Is Coming Back? Researchers Are on It — the news story that sparked this post
